MRK - Merck & Co., Inc.
| Previous Close | 78.94 |
| Open | 79.66 |
| Bid | 79.00 x 1400 |
| Ask | 0.00 x 900 |
| Day's Range | 79.34 - 80.13 |
| 52 Week Range | 52.83 - 80.19 |
| Volume | 10,387,517 |
| Avg. Volume | 13,248,006 |
| Market Cap | 207.536B |
| Beta (3Y Monthly) | 0.38 |
| PE Ratio (TTM) | 34.40 |
| EPS (TTM) | 2.32 |
| Earnings Date | Apr 30, 2019 |
| Forward Dividend & Yield | 2.20 (2.79%) |
| Ex-Dividend Date | 2019-03-14 |
| 1y Target Est | 82.52 |
- Reuters•23 hours ago
Merck, Pfizer drug combo extends kidney cancer survival -study
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
- Business Wire•yesterday
KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine Also Showed Risk o
- Moody's•2 days ago
Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Merck & Co., Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Market Realist•2 days agoWhat Are Merck’s Key Growth Drivers for 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal
Market Realist•2 days agoComparing Dividends and Tax Rates for MRK and GSK in 2019
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
- Market Realist•2 days ago
Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
- Business Wire•2 days ago
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
- GlobeNewswire•2 days ago
Cerecor Announces CERC-301 Granted U.S. Patent
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202,363 ("the ‘363 patent") on Feb. 12, 2019, which is directed to CERC‑301, an oral, NR2B-specific, NMDA receptor antagonist. CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in 375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.
- Zacks•3 days ago
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
- Market Realist•3 days ago
MRK or GSK: Which Is Expected to Report Faster EPS Growth?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
- Market Realist•3 days ago
Is MRK or GSK Expected to Report Faster Revenue Growth in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
- Market Realist•3 days ago
What Analysts Recommend for Merck and GlaxoSmithKline This Month
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?Share price movements On February 11, Merck & Co. (MRK) closed at $76.71, 1.04% lower than its previous closing price, 45.20% higher than its 52-week low of $52.83, and 4.34% lower
- Reuters•3 days ago
Merck to further study Keytruda in prostate cancer after early success
Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity ...
- Zacks•3 days ago
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
- The Wall Street Journal•3 days ago
[$$] Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran
Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran By Kim S. Nash Good day. Is physical damage caused by cyber incidents covered by property insurance? Is data property? Who determines when a cyberattack is an act of war? And how? In lawsuits against their insurance firms, pharmaceutical firm Merck & Co.
- Business Wire•3 days ago
Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
Research Program Expanded Based on Promising Data Shown with KEYTRUDA® in Combination with LYNPARZA® , Chemotherapy and Anti-Hormone Agents in Patients wi
- TheStreet.com•3 days ago
AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook
AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing ...
- Zacks•4 days ago
Top Research Reports for ExxonMobil, Merck & Danaher
Top Research Reports for ExxonMobil, Merck & Danaher
- Zacks•5 days ago
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
- Zacks•5 days ago
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
- Zacks•5 days ago
Stock Market News For Feb 12, 2019
Markets closed mostly higher on Monday as fresh rounds of trade talks between the United States and China began.
- Zacks•5 days ago
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
- Zacks•5 days ago
Bristol-Myers' Sprycel Gets European Nod for Label Expansion
Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
- American City Business Journals•5 days ago
Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target
Nonalcoholic steatohepatitis, or "fatty liver" disease, is believed to affect some 20 million people in the United States, and a dearth of FDA-approved treatments makes it a big target for drug developers.
